safinamide has been researched along with toloxatone in 4 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (toloxatone) | Trials (toloxatone) | Recent Studies (post-2010) (toloxatone) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 60 | 6 | 21 |
| Protein | Taxonomy | safinamide (IC50) | toloxatone (IC50) |
|---|---|---|---|
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 3.26 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 2.8479 | |
| Amine oxidase [flavin-containing] A | Bos taurus (cattle) | 0.3802 | |
| Amine oxidase [flavin-containing] B | Mus musculus (house mouse) | 3.92 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mostert, S; Petzer, A; Petzer, JP | 2 |
| Abramov, IG; Chirkova, ZV; Filimonov, SI; Kabanova, MV; Petzer, A; Petzer, JP; Suponitsky, KY | 1 |
| Baykov, S; Chirkova, Z; Engelbrecht, I; Korsakov, M; Osipyan, A; Petzer, A; Petzer, JP; Sapegin, A; Shetnev, A | 1 |
4 other study(ies) available for safinamide and toloxatone
| Article | Year |
|---|---|
Inhibition of monoamine oxidase by benzoxathiolone analogues.
Topics: Benzoxazoles; Humans; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Isoforms; Structure-Activity Relationship | 2016 |
An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase.
Topics: Crystallography, X-Ray; Models, Molecular; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2016 |
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
Topics: Benzoquinones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
Topics: Dose-Response Relationship, Drug; Humans; Imidazoles; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Structure-Activity Relationship | 2019 |